Group 1 - Company held its fourth extraordinary general meeting of shareholders on December 24, 2024, to approve the proposal for repurchasing A-shares [1] - The total amount planned for the A-share repurchase is between 60 million yuan and 100 million yuan, with a maximum repurchase price of 45.00 yuan per share [2] - As of August 31, 2025, the company has repurchased a total of 13,383,055 A-shares, accounting for 1.48% of the total share capital, with a total expenditure of approximately 490.93 million yuan [2] Group 2 - The company will conduct H-share repurchases through the Hong Kong Stock Exchange, with each repurchase price not exceeding 105% of the average closing price over the previous five trading days [3] - H-shares repurchased will also be used for capital reduction [3] - The company will comply with relevant disclosure obligations as per the Shenzhen Stock Exchange and Hong Kong Stock Exchange regulations [3]
丽珠医药回购进展：A股已回购1338.31万股，耗资近4.91亿元